Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAN-001 in Combination With Pembrolizumab +/- Chemotherapy in Advanced NSCLC
NCT07910942Phase 1Not yet recruiting
- Sponsor
- Kanvas Biosciences
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 2
01
Overview
Phase 1, open-label trial of KAN-001 in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Kanvas Biosciences. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
KAN-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07910942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910942.